ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to investigate glycaemic control and safety in Chinese adults with type 2 diabetes (T2D) receiving fixed-ratio combination of insulin degludec and liraglutide (IDegLira) in real-world clinical practice.
methodsThe Tianjin Health and Medical Big Data Super Platform was utilised to assess clinical characteristics, glycaemic control, and safety of Chinese adults with T2D receiving IDegLira between March 5, 2022 and June 30, 2024. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to day 180. Secondary endpoints included change in HbA1c by baseline characteristics; change in fasting plasma glucose (FPG), postprandial glucose (PPG), and daily insulin dose; and treatment persistence. Exploratory endpoints included hypoglycaemic events and gastrointestinal adverse events (GI AEs).
resultsEligible participants were included in the full analysis set and safety analysis set (both n = 12,103), and participants receiving IDegLira for 180 days were included in the effectiveness analysis set (n = 3062). The mean (SD) change in HbA1c, FPG, PPG, and insulin dose after 180 days from baseline was - 1.08% (1.87, p < 0.001), - 2.34 mmol/L (3.61, p < 0.001), - 2.10 mmol/L (4.86, p < 0.001), and - 4.95 U/day (21.93, p < 0.001), respectively. Subgroup analyses of HbA1c change demonstrated that IDegLira decreased HbA1c significantly, irrespective of prior treatment, age, most baseline HbA1c, daily insulin dose, and fasting C-peptide quartiles. Median treatment persistence duration was 141.67 days (95% CI 135.67-146.67). Low percentages of patients reported hypoglycaemia (0.7%) or GI AEs (11.1%).
conclusionsIDegLira statistically improved glycaemic control by reducing HbA1c, FPG, and PPG levels in the Chinese population with T2D, with a favourable safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.